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Depression is known to be accompanied by abnormalities in the hypo-
thalamic–pituitary–adrenal (HPA) axis and in the hypothalamic-pituitary-
thyroid axis. Little attention however, has been given to possible reproductive
hormonal abnormalities in depression, despite suggestions that women
are more vulnerable to depressive symptoms, particularly during times of
rapid changes in gonadal steroid secretion. This article focuses on reproduc-
tive hormone status in two mood disorders: major depression and premen-
strual syndrome (PMS).
Differences in rates of depression in men and women
Interest in reproductive hormones and depression date to the observa-
tions that depression is more common in women, specifically during times
of changing ovarian steroids such as postpartum. Although it was known
that more women seek treatment for major depression than men, initial stud-
ies focused on ascertaining if these sex differences were real or the result of
assessment or treatment bias. The National Institute of Mental Health
(NIMH) epidemiological catchment area (ECA) studies examining rates
of major depression in the community at large [49,66,68] made explicit that
the greater incidence and prevalence of depression in women (8% to 9% for
depression plus dysthymia) were real. The reasons for this higher incidence
of major depression in women remains unclear. In an excellent, now classic
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review of sex difference in the prevalence of depression, Weissman and Kler-
man [87] described a number of possible ‘‘etiologies’’ for the greater preva-
lence of depression in women. None of the current psychological theories,
however, account adequately for the greater prevalence of depressive disor-
ders in women. Common to the various hypotheses about increased preva-
lence of depressive disorders in women is the concept that environmental
factors contribute to the onset of major depression. Significant environmen-
tal risk factors include: loss of mother in childhood, stresses of family and
job, lack of a close emotional relationship with ones spouse, marital dis-
cord, the presence of three children under the age of 14 in the home, sexual
discrimination, and victimization/sexual abuse [87]. All of these factors may
be conceptualized as psychosocial stressors that contribute to the onset of
major depression in vulnerable individuals. The demonstration of overactiv-
ity in the main stress hormone system of the body, the HPA axis, in patients
with major depression, lends credence to the hypothesis that stress contrib-
utes to the onset of major depression [11,70,74].
In addition to psychosocial stressors, biological, and genetic components
contribute to depression. Genetic studies have demonstrated familial in-
heritance for both unipolar and bipolar depression [23,38,89]. Both of these
disorders are primarily episodic and recurrent, with increasing frequency of
major depressive episodes developing over time. In women with a previous
episode of major depression, rapidly changing gonadal steroid concentra-
tions, such as those occurring premenstrually or postpartum, mark particu-
larly vulnerable times for the occurrence of depressive symptoms. Early
studies by Reich and Winokur [65] suggested that the risk of a postpartum
depressive episode in women with a previous episode of major depression is
30% versus 8% at other times. Studies by O’Hara et al. [53,54] confirm that a
history of depressive episodes increases the risk of both postpartum ‘‘blues’’
and postpartum major depression. Studies by Halbreich et al. [29,30] sug-
gested that hormonal changes occurring premenstrually may affect mood.
When not in a depressive episode, 62% of women with a history of past
major depressive episodes reported the occurrence of premenstrual mood
changes and biological symptoms typical of major depressive disorder, lead-
ing the authors to hypothesize that changes in gonadal steroid concentra-
tions may contribute to depressive symptoms. Despite these various
suggestions that reproductive hormones may play a role in mood disorders,
the hypothalamic–pituitary–gonadal (HPG) axis has received little examina-
tion in depression, and the few existing studies have reached inconclusive
findings, perhaps because they have tended to include men with pre- and
postmenopausal women in the data analysis, rather than analyzing these
groups separately. In their 1977 review on sex differences in depression,
Weissman and Klerman [87] noted that ‘‘no study could be located that cor-
related clinical state with female endocrines, utilizing modern endocrinolo-
gical methods or sensitive quantitative hormonal assays.’’ This only
recently has begun to change.
64 E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
Stress and the reproductive axis
Although the effects of stress on reproduction long has been recognized
by clinicians, one of the earliest basic science reports of stress affecting fer-
tility rates dates back to Christians observations on population density and
reproductive cycles in lemmings and voles and the link of the infertile peri-
ods cycles to adrenal steroids [16]. The isolation and sequencing of corti-
cotropin releasing factor [85] coupled with observations of Knobil on
inhibition of luteinizing hormone (LH) pulses in awake primates restrained
in a primate chair gave further impetus to the investigation of the effects of
stress on the reproductive axis [39]. To understand the impact of stress on
this axis, this article presents a brief overview of the HPG axis and then
describe the effects of stress on the reproductive axis.
The HPG axis, which regulates gonadal steroid production, is a multiple
level hormonal system involving brain and pituitary with feed forward and
feedback elements. The secretion of the principal gonadal steroids, estrogen
and progesterone, is governed by cyclic changes in ovarian follicular and cor-
pus luteum development over the course of the menstrual cycle. Critical to the
proper functioning and timing of the monthly hormonal cycle is the pulsatile
secretion of gonadotropin-releasing hormone (GnRH). GnRH secretion
from the hypothalamus drives the secretion of LH and follicle stimulating
hormone (FSH) from pituitary gonadotropes [17]. Estradiol exerts a negative
feedback on FSH secretion and both negative and delayed positive feedback
effects on LH secretion [36]. The change in estradiol feedback from negative
to positive late in the follicular phase is complemented by rising progesterone
and results in the midcycle surge in LH necessary for ovulation.
Gonadal steroids exert negative feedback effects on the amplitude and fre-
quency of GnRH pulses and through this mechanism (in addition to direct
actions on the pituitary) inhibit the secretion of LH and FSH. Circadian
changes in LH secretion are not as prominent as those of the HPA axis [35].
Early studies with corticotropin-releasing factor (CRF) by Rivier indi-
cated clear inhibitory effects of central CRF injection on GnRH secretion
and subsequent studies in a number of species have continued to document
inhibitory effects of CRF on GnRH and LH secretion [21,22,45,51,55,57]
(Fig. 1). Additionally, central opioids, particularly b-endorphin, exert a
tonic inhibition on GnRH secretion [21], and it appears that central CRH
can regulate arcuate b-endorphin release. CRH is distributed widely in the
brain and appears to mediate a number of the behavioral effects of stress,
including anorexia and anxiety, and to initiate the hormonal cascade of
the HPA axis. The effects of CRH on GnRH secretion may be both direct
and indirect: CRH neurons can synapse with GnRH neurons [45], and
CRH can function as a secretagogue for b-endorphin secretion from the
arcuate b-endorphin system [52]. These inhibitory effects of gonadal steroids,
b-endorphin and CRH appear to result from central actions of these hor-
mones (i.e., actions in the brain).
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In addition to the clear inhibition of GnRH secretion by CRH, older
studies suggested that peripheral elements of the HPA axis may affect LH
secretion. Several studies have demonstrated that corticotropin (ACTH)
administration reduces the increase in serum LH concentrations following
ovariectomy or orchidectomy [46,80]. This effect depends on the presence
of the adrenal, and may involve adrenal production of gonadal steroids
which is regulated by ACTH [61]. Glucocorticoids also may exert inhibitory
effects on GnRH secretion or LH responsiveness to GnRH, including direct
effects of cortisol on the gonadotrope [67,83]. A glucocorticoid responsive
element (GRE) is present on the GnRH gene, providing the potential for
glucocorticoids to modulate GnRH gene expression and this has been
observed in several hypthalamus-derived cell lines [3,15]. Diminished LH
response to GnRH following long-term prednisolone treatment, has been
found in women [75]. Furthermore, in women with Cushings Disease, men-
strual cycle irregularity correlate with hypercortisolemia [41]. Saketos et al.
Fig. 1. Interactions between HPA and hypothalamic–adrenal–ovarian axes. Solid line¼
stimulatory actions; dotted line ¼ inhibitory actions. From Young EA, Korzsun A. Psycho-
neuroendocrinology of depression: hyphothalamic–pituitary–gonadal axis. Psych Clin N Am
1998;21:313; with permission.
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[76] observed slowing of LH pulse frequency with hydrocortisone infusion,
although other investiators have not confirmed this [77]. b-Endorphin
secreted by pituitary corticotropes also may be able to affect GnRH secre-
tion by way of actions on the median eminence. In a series of studies by
Ferin et al. in rhesus monkeys, peripherally administered CRH decreased
LH pulse frequency and integrated LH secretion over several hours [24,
25,55,90,91]. This effect involved a glucocorticoid regulated endogenous
opioid system, suggesting the involvement of the anterior pituitary proopio-
melanocortin (POMC) system.
Hypothalamic control of gonadotropins
The pulsatile secretion of GnRH is driven by a pulse generator in the ar-
cuate nucleus of the hypothalamus [39]. The structural characteristics of indi-
vidual pulses of GnRH and the time series pattern of their secretion controls
frequency, amplitude and most likely nature of LH secretory episodes. Stud-
ies in sheep examining GnRH secretion into hypophyseal portal blood
demonstrate a clear one to one correspondence between GnRH secretory
pulses in portal blood and LH secretory pulses in peripheral circulation
[17]. This pulsatile pattern of GnRH secretion is critical for the control
of serum LH, FSH, and ovulation. Indeed, continuous administration of
GnRH in a nonpulsatile pattern results in suppression of ovulation as effect-
ively as inadequate secretion of GnRH. Studies in primates with arcuate
lesions have demonstrated that administration of GnRH pulses in frequen-
cies that are too fast or too slow result in low serum concentrations of LH
[5]. Because access to the hypophyseal portal circulation in women cannot
be gained to measure actual GnRH secretory dynamics, LH secretory pulses
in the peripheral circulation are used as the marker of GnRH secretory
pulses. In humans, the follicular phase of the menstrual cycle is character-
ized by reasonably constant amplitude LH pulses every 1 to 2 hours [62].
During the luteal phase, pulse amplitude becomes much more variable,
and pulse frequency decreases to one pulse every 2 to 6 hours.
Similarities among depression, exercise-induced amenorrhea,
anorexia nervosa and hypothalamic amenorrhea
Major depression is accompanied by increased cortisol secretion, resist-
ance to the negative feedback effects of cortsiol and dexamethasone, and
a decreased ACTH response to CRH administration [12,27,30,34,42,58,70,
93,95]. In addition to depression, several other disorders of women have been
described with HPA axis dysregulation similar to that seen in depres-
sed women. These include exercise-induced amenorrhea, anorexia ner-
vosa, and hypothalamic amenorrhea. In these syndromes, amenorrhea is a
primary presenting problem. Hypercortisolemia also has been observed,
indicating overactivity of the HPA axis [7,13,32,44,82,86]. In all three
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syndromes CRH has been used as a challenge to evaluate pituitary and adre-
nal function. The response to CRH is similar to that seen in depressed patients
(i.e. diminished ACTH or cortisol responses), suggesting that high baseline
cortisol exerts negative feedback effects on the hormonal responses to CRH
[9,26,33]. In anorexia nervosa, the hormonal abnormalities in HPA and
HPG axes are secondary to weight loss. Weight restriction and low body
weight also is observed in exercise-induced amenorrhea, and low body
weight has been reported in hypothalamic amenorrhea. Even relatively mild
degrees of weight loss in normal weight or obese subjects can lead to disturb-
ances in both axes as manifested by resistance to dexamethasone and by
disturbances in menstrual regularity or amenorrhea [8,18,59,73]. Conse-
quently, these amenorrheic syndromes present with evidence of weight loss,
increased HPA axis activation, disruptedHPG functioning, and amenorrhea.
In common with the findings in these syndromes, weight loss and HPA
axis overactivity are frequent findings in major depression, and increased
cerebrospinal fluid levels of CRH have been reported in both depression
and anorexia nervosa [37,50]. The well-demonstrated inhibitory effects of cen-
tral CRHonGnRH secretion suggest that if peripheral HPA axis overactivity
reflects central CRH overactivity, then HPA axis disturbances should be
accompanied by disturbances in GnRH secretion. The influence of this pre-
sumed CRH overactivity on gonadal hormone secretion only recently has
been evaluated critically in men and women with major depression.
The disturbances in GnRH secretion in anorexia nervosa and hypothala-
mic amenorrhea have been evaluated primarily by examining the character-
istics of LH pulsatile activity. In anorexia nervosa, LH secretory patterns
may revert to prepubertal levels of low, nonpulsatile secretion, or to a pub-
ertal pattern of entrainment of LH secretion to the sleep cycle. Studies by
Reame et al. on women with hypothalamic amenorrhea demonstrated that
LH secretion in the follicular phase is slowed to the rate normally observed
during the luteal phase [62]. In these individuals, LH and FSH responses to
GnRH appear normal, indicating that the reduced pulse frequency is not
secondary to pituitary changes but presumably because of changes in the
GnRH pulse generator.
Reproductive hormone studies in major depression
A number of older studies of reproductive hormones in depression
[1,2,4,6,10,19,20,43,69,72,84,88] examined mean LH levels but are problem-
atic for interpretation, since they are based on isolated measurements in a
dynamic system. Furthermore, these studies included men, premenopausal
women in both follicular and luteal phases, and postmenopausal women
without examining the influences of these factors separately. During the
luteal phase, LH pulses are large (amplitudes of 1 to 10 mIU/mL) and infre-
quent (e.g., once every 6 hours). During the follicular phase, LH pulses are
frequent but of smaller amplitude (2 to 5 mIU/mL). Finally, postmenopau-
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sally, absolute concentrations of LH can reach 30 to 50 mIU/mL. Further-
more, ‘‘average LH concentrations’’ miss a substantial portion of the infor-
mation contained in this system, in which frequency modulation plays a
critical role in the normal functioning of the axis, influencing both regula-
tion of ovulation and subsequent ovarian hormone secretion.
In depression, response to GnRH has been assessed by three groups.
Using a high dose of GnRH (250 lg), Winokur et al. reported a normal
LH and FSH response to GnRH in a group of male and female depressed
patients that included both pre- and postmenopausal women [88]. Measure-
ments of LH concentration in a single blood sample revealed lower basal
LH concentrations in depressed than in control postmenopausal women.
The sample size was not large enough to analyze the baseline or response
to GnRH stimulation data separately for men and pre- versus postmeno-
pausal women. Unless GnRH secretion is markedly reduced, however, an
abnormal response to GnRH would not be expected, since altered GnRH
secretion is a central, not peripheral, phenomenon. Brambilla et al. [10] used
a lower dose of GnRH (150 lg) to examine LH response to GnRH in 15
pre- and 32 postmenopausal depressed women. They noted a decreased
LH response to GnRH in both groups. Measurement of serum LH in four
samples drawn over the course of an hour again demonstrated lower base-
line LH concentrations in postmenopausal depressed women than in their
matched controls. Studies by Unden et al. [84], again examining depressed
patients of both sexes and not analyzed separately, observed no change in
baseline or GnRH-stimulated LH and FSH secretion.
Recent studies have begun using modern understanding of reproductive
hormones to examine LH pulsatility and other reproductive hormone levels
in depression. OToole and Rubin [56] examined mean LH and FSH levels
in depressed women and menstrual status but not phase–matched control
women every half hour over 16 hours, and found normal mean levels of
LH and FSH. A study by Meller et al. [47], examining LH pulsatility in
10 depressed follicular phase women and 13 control women found no differ-
ence in number of LH pulses over an 8 hour period, although significantly
increased LH amplitude and LH area under the curve were observed in
depressed women. Schweiger et al. [81] examined pulsatile LH secretion
and mean LH, FSH, and testosterone in depressed men and normal controls
using frequent sampling methods. They found normal LH pulsatility and
normal mean LH and FSH but decreased mean testosterone in men with
major depression, leading them to conclude that gonadal function may be
disturbed in men with a depressive episode.
The authors recently completed a study of 25 premenopausal depressed
women (Fig. 2) [93]. Each woman was matched individually on age and men-
strual cycle day to a healthy normal control woman. Samples were drawn
every 10 minutes for 12 hours, and data were analyzed for LH pulsatility,
mean FSH, estradiol, and progesterone. Twelve patients and their matched
controls were studied in the follicular phase and 13 in the luteal phase. The
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authors found the expected follicular-luteal phase differences in mean FSH,
and estradiol, and LH pulse amplitude, pulse half-life, and pulse number.
The authors found no significant difference between patient and controls
on any measure of LH except the half-life of LH, which was significantly
shorter in patients than in controls. Furthermore, they found decreased mean
estradiol in the follicular phase in depressed women. Given the normal pro-
gesterone levels in the luteal phase in depressed women, however, there
appears to be no ovulatory defect in depressed women. These data, combined
with the previous data of Schweiger [81] and Meller [47] suggest that the cri-
tical neuronal circuits controlling GnRH secretion and GnRH pulsatility are
normal in depressed women. Furthermore, there was no relationship between
mean 24 hour cortisol and any LH parameter in the study, despite the pre-
sence of hypercortisolemia in some subjects. Likewise, the depressed subjects
in the reports by Schweiger et al. [81] demonstrated activation of the HPA
axis as reflected by increased cortisol secretion. Still, there may be a gonadal
defect in major depression leading to lower testosterone in depressedmen and
lower estradiol in follicular phase depressed women. Alternatively, it may be
that individuals with low estradiol are more vulnerable to major depression.
(in men, testosterone is converted to estradiol in vivo and exerts a number of
effects through estradiol receptors) (Fig. 3).
Fig. 2. (A) Normal LH profile during luteal phase as defined by 10 minute sampling over 12
hours. (B) Normal LH profile during follicular phase as defined by 10 minute sampling over
12 hours.
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PMS and ovarian hormones
One of the most well-studied mood disorders with respect to the influence
of ovarian steroids on mood is PMS or late luteal phase disorder (DSM-
IIIR). The experience of researchers in the field is uniform in that many more
women report significant variations in mood premenstrually in retrospective
reports than are found to have symptoms with prospective studies. Thus, it is
necessary to define the study population carefully and limit both endocrine
investigations and treatment to women with clear luteal phase depressive
symptoms who are well during the follicular phase. Studies by Reame et al.
[64] used state-of-the art assays and optimal sampling frequency to investi-
gate LH, FSH, pulse frequency, and amplitude in follicular, mid- and late
luteal phases of the menstrual cycle, and examine estradiol and progesterone
levels at these three time points. At no time were estradiol and progesterone
different between women with PMS compared with controls. LH pulse fre-
quency was also similar in both groups with parallel changes across the men-
strual cycle. Mean FSH was higher in the PMS group at mid luteal phase,
although the meaning of an isolated change in FSH is hard to explain. Thus,
the data do not suggest an alteration in GnRH secretion or ovarian steroids
in women with PMS. Despite the absence of documented abnormalities in
these hormone systems, a number of studies suggest that manipulations of
ovarian steroids can improve the symptoms.
One of the best documented effective treatments is elimination of men-
strual cycling with leuprolide, a GnRH agonist, that improves mood.
Fig. 3. Plasma estradiol in untreated depressed women. Open bar ¼ control; solid bar ¼
depressed.
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Because this also leads to hypoestrogenism, which affects bone density and
cardiovascular disease, it is necessary to add both steroid hormones. In the
study by Mortola et al. [48], just the addition of a placebo with the sugges-
tion that it might make mood symptoms worse, caused a significant worsen-
ing in mood symptoms. Still, addition of conjugated equine estrogen with or
without medroxyprogesterone acetate (MPA) while still on leuprolide did
not lead to a relapse in depressive symptoms. Not all studies have agreed
that progesterone can be added back without significant worsening of symp-
toms. In fact, this may depend upon the dose of progesterone, since higher
doses cause relapse and administration of oral contraceptives which have
more potent progesterone than MPA exacerbate PMS [31]. Although it
appears that some aspect of menstrual cycling may exacerbate mood pro-
blems in vulnerable women, whether this extends to women with major
depression is unclear. Finally, progesterone has been used for the treatment
of PMS despite its documented lack of effectiveness. Although clearly not
effective, it does not appear to worsen mood symptoms [92].
Because it was believed that the symptoms of PMS are related to delayed
effects of progesterone on mood, several studies have investigated the effects
of RU486, a progesterone antagonist on mood symptoms. In studies by
Schmidt et al. [79], the creation of an artificial follicular phase during the
second half of the menstrual cycle by the use of RU486 plus human chorio-
nic gonadotropin did not result in a reduction of mood symptoms. Likewise
blockade of progesterone’s action led to early menses with depressive symp-
toms still occurring. Likewise, the study by Chan, et al. [14] using a random-
ized double blend placebo controlled cross-over design for 6 months showed
no effectiveness of RU486 on mood symptoms. Thus, although generally
believed that PMS is related to changes in CNS neurotransmitter systems
caused by progesterone, the data did not support that progesterone block-
ade affects these mood symptoms. This led Rubinow and Schmidt [71] to
propose that PMS is a cyclical mood disorder ‘‘entrained’’ to the menstrual
cycle, rather than a disorder caused by changes in ovarian steroids.
Ovarian steroids’ effects on mood in major depression
As reviewed previously, the changes in sex steroids in major depression are
small, it is possible, however, that depressed women may be more resistant to
the beneficial effects of ovarian steroids on mood. An early report by Prange
et al. [60], suggested that estrogen could act to augment the response to anti-
depressants. Many clinicians routinely provide estrogen supplementation to
postmenopausal depressed women to improve mood, although even this
practice has not been documented in placebo controlled trials. Only recently
has antidepressant response been examined by sex and menopausal status to
determine if ovarian steroids influence treatment response. In a large multi-
centered collaborative study comparing sertraline with imipramine [40], it
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was observed that premenopausal women showed a greater drop out rate
because of side effects in the imipramine group, while men and postmenopau-
sal women dropped out more on the sertraline. There was a trend level finding
that premenopausal women responded better to sertraline than imipramine
while postmenopausal women responded better to imipramine. Additionally,
women on oral contraceptives responded even better to he sertraline than
premenopausal women. These data further suggest the need for placebo con-
trolled trials of estrogen augmentation to depression.
Summary
This article has demonstrated that stress andHPA axis activation affect the
reproductive axis.Despite similarities in theHPAaxis picture betweenwomen
with major depression and those with hypothalamic amenorrhea and exercise
or nutritional amenorrhea, no abnormalities in LH secretion have been docu-
mented in major depression. Lower estradiol in the follicular phase in
depressed women and lower testosterone in depressed men however, have
been observed [81,92]. Although PMS would appear to be the best candidate
for a mood disorder associated with abnormalities in reproductive hormones,
no abnormalities in LH, estradiol or progesterone have been documented in
PMS either [62]. Similarly, blockade of progesterone appears to be ineffective
as a treatment for PMS [79]. Complete elimination of monthly cycling with
leuprolide improves mood, however. No published studies have examined
womenwithmajor depression to determinewhether leuprolidewill exacerbate
or improve depressive symptoms. Some studies suggest beneficial effects of
estrogen on mood in postmenopausal women, but no placebo controlled stu-
dies have explored estrogen augmentation in the treatment of major depres-
sion in either post- or premenopausal women, although estrogen is
beneficial in women with perimenopause-related mood disorders [78].
References
[1] Altman N, Sachar EJ, Gruen PH, Holpen JS, EtoS Reduced plasma LH concentration in
postmenopausal depressed women. Psychosom Med 1975;37:274–83.
[2] Amsterdam JD, Winokur A, Caroff S, Snyder P. Gonadotropin release after administra-
tion of GnRH in depressed patients and healthy volunteers. J Affect Disord 1981;3:367–80.
[3] Attardi B, Tsujii T, Friedman R, Zeng Z, Roberts JL, Dellcrode T, Pfaff DW, Chan-
dran UR, Sullivan MW. Glucocorticoid repression of gonadotropin-releasing hormone
gene expression and secretion in morphologically distinct subpopulations of GT1–7cells.
Mol Cell Endocrinol 1997;131:241–55.
[4] Baumgartner A, Graf KJ, Kurten I, Meinhold H, Scholz P. Neuroendocrinological
investigations during sleep deprivation in depression. I. Early morning levels of thyro-
tropin, TH, cortisol, prolactin, LH, FSH, estradiol, and testosterone. Biol Psychiatry
1990;28:556–68.
[5] Belchetz PE, Plant TM, Nakai Y. Keogh EJ, Knobil E. Hypophyseal responses to con-
tinuous and intermittent delivery of gonadotropin-releasing hormone. Science 1978;202:
631–33.
73E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
[6] Benkert O. Studies on pituitary hormones and releasing hormones in depression and sexual
impotence. Prog Brain Res 1975;42:25–36.
[7] Berga SL, Mortola JF, Girton L, Suh B, Laughlin G, Pham P, Yen SS. Neuroendocrine
aberrations in women with functional amenorrhea. J Clin EndocrinolMetab 1989;68:301–8.
[8] Berger M, Pirke K, Doerr P, Krieg JC, Van Zessen D. Influence of weight loss on the
dexamethasone suppression test. Arch Gen Psychiatry 1983;40:585–6.
[9] Biller BM, Federoff HJ, Koenig JI, Klibanski A. Abnormal cortisol secretion and res-
ponses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin
Endocrinol Metab 1990;70:311–17.
[10] Brambilla F, Maggioni M, Ferrari E, Scarone S, Catalano M. Tonic and dynamic gona-
dotropin secretion in depressive and normothymic phases of affective disorders. Psychiatry
Res 1990;32:229–39.
[11] Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression I. Limbic
system-adrenocortical dysfunction. Arch Gen Psychiatry 1976;33:1039–44.
[12] Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskeh RF, James NM,
Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young EA. A specific laboratory test for the
diagnosis of melancholia: Standardization, validation, and clinical utility. Arch Gen
Psychiatry 1981;38:15–22.
[13] Casanueva FF, Borras CG, Burguera B, Muruais C, Fernandez M, Devesa J. Steroids and
neuroendocrine function in anorexia nervosa. J Steroid Biochem Molec Biol 1987;27:
635–40.
[14] Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during
low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994;84:
1001–5.
[15] Chandran UR, Attardi B, Friedman R, Oong KW, Roberts JL, DeFranco DB. Gluco-
cortoid receptor-mediated repression of gonadotropin-releasing hormone promoter activity
in GT1 hypothalamic cell lines. Endocrinology 1994;134(3):1467–74.
[16] Christian JJ. Population density and reproductive efficiency. Biol Reprod 1971;4:248–94.
[17] Clarke IJ, Cummins JT. The temporal relationship between gonadotropin releasing hor-
mone (GnRH) and leutenizing hormone (LH) secretion in ovariectomized ewes. Endo-
crinology 1982;111:1737–9.
[18] Edelstein CK, Roy-Byrne P, Fawzy FI, Dornfeld L. Effects of weight loss on the
dexamethasone suppression test Am J Psychiatry 1983;140:338–41.
[19] Ettigi PG, Brown GM, Seggie JA. TSH and LH responses in subtype of depression.
Psychosom Med 1979;41:203–8.
[20] Ettigi PG. Anterior pituitary function in depression. In: Bhatnagar AS, (ed): The anterior
pituitary gland. New York: Raven Press; 1982. p. 405–414.
[21] Ferin M, Vande Wiele R. Endogenous opioid peptides and the control of the menstrual
cycle. Eur J Obstet Gynecol Reprod Biol 1984;18:365–73.
[22] Gambacciani M, Yen SS, Rasmussen DD. GnRH release from the mediobasal hypo-
thalamus: In vitro inhibition by corticotropin-releasing factor. Neuroendocrinology 1986;
43:533–6.
[23] Gershon ES, Dunner DL, Goodwin FK. Toward a biology of affective disorders. Arch Gen
Psychiatry 1971;25:1–5.
[24] Gindoff P, Xiao E, Luckhaus J, Ferin M. Dexamethasone treatment prevents the inhibitory
effect of corticotropin-releasing hormone (CRH) on gonadotropin release in the primate.
Neuroendocrinology 1989;49:202–6.
[25] Gindoff PR, Ferin M. Endogenous opioid peptides modulate the effect of corticotropin
releasing factor on gonadotropin release in the primate. Endocrinology 1987;121:837–42.
[26] Gold PW, Gwirtsman H, Avgerinos P, Nieman LK, Gallucci WT, Kaye W, Jimerson D,
Ebert M, Rittmaster R, Loriaux DL, Chrousous GP. Abnormal hypothalamic pituitary
adrenal function in anorexia nervosa: pathophysiological mechanisms in underweight and
weight corrected patients. N Engl J Med 1986;314:1335.
74 E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
[27] Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post
RM, Picker D, Gallucci W. Response to corticotropin-releasing hormone in the hyper-
cortisolism of depression and Cushing’s disease. N Engl J Med 1986;314:1329–35.
[28] Halbreich U, Asnis GM, Schindledecker R, et al. Cortisol secretion in endogenous
depression I. Basal plasma levels. Arch Gen Psychiatry 1985;42:909–14.
[29] Halbreich U, Endicott J, Goldstein S, Nee J. Premenstrual changes and changes in gonadal
hormones. Acta Psychiatr Scand 1986;74:576–86.
[30] Halbreich U, Vital-Herne J, Goldstein S, Zander K. Sex differences in biological factors
putatively related to depression. J Affect Disord 1984;7:223–33.
[31] Hammaback S, Backstron T, Holst J, von Schoultz B, Lyrenas S. Cyclical mood changes as
in premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal
replacement therapy. Acta Obstet Gynecol Scand 1985;64:393–7.
[32] Hohtari H, Elovainio R, Salminen K, Laatikainen T. Plasma corticotropin-releasing
hormone, corticotropin, and endorphins at rest and during exercise in eumenorrheic and
amenorrheic athletes. Fertil Steril 1988;50:233–8.
[33] Hohtari H, Salminen-Lappalainen K, and Laatikainen T. Response of plasma endorphins,
corticotropin, cortisol, and luteinizing hormone in the corticotropin-releasing hormone
stimulation test in eumenorrheic and amenorrheic athletes Fertil Steril 1991;552:276–280.
[34] Holsboer F, Bardeleden U, Gerken A, et al. Blunted corticotropin and normal cortisol
response to human corticotropin-releasing factor in depression. N Engl J Med 1984;
311:1127.
[35] Jaffe RB, Plosker S, Marshall L, Martin MC. Neuromodulatory regulation of gona-
dotropin-releasing hormone pulsatile discharge in women. Am J Obstet Gynecol 1990;163:
1727–31.
[36] Karsch FJ, Foster DK, Bittman EL, et al. A role of estradiol in enhancing LH pulse
frequency during the follicular phase of the estrous cycle of sheep. Endocrinology
1983;113:1333–9.
[37] Kaye WH, Gwirtsman HE, George DT, Ebert MH, Jimerson DC, Tomai TP, Chrouos
GP, Gold PW. Elevated CSF levels of immunoreactive CRH in anorexia nervosa:
Relationship to state of nutrition, adrenal function and intensity of depression. J Clin
Endocrinol Metab 1987;64:203–8.
[38] Kendler KS, Kessler RC, Neale MC, Heath AC, Eaves LJ. The prediction of major
depression in women: Toward an integrated etiological model. Am J Psychiatry 1993;
150:1139–1148.
[39] Knobil E. The GnRH pulse generator. Am J Obstet Gynecol 1990;163:1721–7.
[40] Kornstein SG, Schatzberg AF, Thase ME, Yenkers KA, McCullough JP, Keitner GI,
Gelenberg AJ, Ryan CE, Hess AL, Harrison W, Davis SM, Keller MB. Gender differences
in treatment response to sertraline versus imipramine in chronic depression. Am J
Psychiatry 2000;157:1445–52.
[41] Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM,
Trainer PJ. Menstrual abnormalities in women with Cushingss disease are correlated with
hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab
1988;83:3083–8.
[42] Linkowski P, Mendelwicz J, LeClercq R, et al. The 24–hour profile of ACTH and cortisol
in major depressive illness. J Clin Endocrinol Metab 1985;61:429.
[43] Linnoila M, Lamberg BA, Rosberg G, Karonen SL, Welin MG. Thyroid hormones and
TSH, prolactin and LH responses to repeated TRH and LRH injections in depressed
patients. Acta Psychiatr Scand 1979;59:536–44.
[44] Loucks AB, Mortola JF, Girton L, Yen SS. Alterations in the hypothalamic-pituitary-
ovarian and the hypothalamic-pituitary-adrenal axes in athletic women J Clin Endocrinol
Metab 1989;68:402–411.
[45] MacLusky NJ, Naftolin F, Leranth C. Immunocytochemical evidence for direct synaptic
connections between corticotrophin-releasing factor (CRF) and gonadotrophin-releasing
75E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
hormone (GnRH)-containing neurons in the preoptic area of the rat. Brain Res 1988;
439:391–5.
[46] Mann D, Jackson G, Bland M. Influence of adrenocorticotropin and adrenalectomy on
gonadotropin secretion in immature rats. Neuroendocrinology 1982;34:20–6.
[47] Meller WH, Zander KM, Crosby RD, et al. Luteinizing hormone pulse characteristics in
depressed women. Am J Psychiatry 1997;154:1545–5.
[48] Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by
combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin
Endocrinol Metab 1991;72:252A–252F.
[49] Myers JK, Weissman MM, Tischler GL, et al. Six month prevalence of psychiatric
disorders in three communities. Arch Gen Psychiatry 1984;41:959–67.
[50] Nemeroff CB, Widerlov E, Bisette G, et al. Elevated concentrations of CSF corticotropin-
releasing-factor-like immunoreactivity in depressed patients. Science 1984;226:1342–4.
[51] Nikolarakis KE, Almeida OF, Herz A. Corticotropin-releasing factor (CRF) inhibits
gonadotropin-releasing hormone (GnRH) release from superfused rat hypothalami in
vitro. Brain Res 1986;377:388–90.
[52] Nikolarakis KE, Almeida OF, Herz A. Inhibition of LH release by CRF may be partially
mediated through hypothalamic beta-endorphin release. NIDAResMonogr 1986;75:403–5.
[53] O’Hara MW. Social support, life events and depression during pregnancy and the puer-
perium. Arch Gen Psychiatry 1986;43:569–73.
[54] O’Hara MW, Schlecte JA, Lewis DA, et al. Prospective study of post-partum blues:
biological and Psychosocial factors. Arch Gen Psychiatry 1991;48:801–6.
[55] Olster DH, Ferin M. Corticotropin-releasing hormone inhibits gonadotropin secretion in
the ovariectomized rhesus monkey. J Clin Endocrinol Metab 1987;65:262–9.
[56] O’Toole SM, Rubin RT. Neuroendocrine aspects of primary endogenous depression—
XIV. Gonadotropin secretion in female patients and their matched controls. Psychoneur-
oendocrinology 1995;20:603–12.
[57] Petraglia F, Sutton S, Vale W, et al. Corticotropin-releasing factor decreases plasma
luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone
release into hypophysial-portal circulation. Endocrinology 1987;120:1083–8.
[58] Pfohl B, Sherman B, Schlecte J, et al. Pituitary/adrenal axis rhythm disturbances in
psychiatric patients. Arch Gen Psychiatry 1985;42:897–903.
[59] Pirke KM, Schweiger U, Lemmel W, et al. The influence of dieting on the menstrual cycle
of young, healthy women. J Clin Endocrinol Metab 1985;60:1174–9.
[60] Prange AJ. Estrogen may well affect response to antidepressant. JAMA 1972;219:143–4.
[61] Putnam CD, Brann DW, Mahesh VB. Acute activation of the adrenocorticotropin-adrenal
axis: Effect on gonadotropin and prolactin secretion in the female rat. Endocrinology
1991;128:2558–66.
[62] Reame NE, Marshall JC, Kelch RP. Pulsatile LH secretion in women with premenstrual
syndrome (PMS): Evidence for normal neuroregulation of the menstrual cycle. Psycho-
neuroendocrinology 1992;2–3:205–13.
[63] Reame N, Sauder SE, Kelch RP, et al. Pulsatile gonadotropin secretion during the human
menstrual cycle: evidence for altered pulse frequency of gonadotropin releasing hormone
secretion. J Clin Endocrinol Metab 1984;59:328–37.
[64] Reame NE, Sauder SE, Case GD, et al. Pulsatile gonadotropin secretion in women with
hypothalamic amennorhea: Evidence that reduced frequency of gonadotropin-releasing
hormone secretion is the mechanism of persistent anovulation. J Clin Endocrinol Metab
1985;61:851–8.
[65] Reich T, Winokur G. Postpartum psychoses in patients with manic depressive disease.
J Nerv Ment Dis 1970;151:60–8.
[66] Reiger DA, Myers JK, Kramer M, et al. The NIMH Epidemiological Catchment Area
Program: Historical context, major objectives, and study population characteristics. Arch
Gen Psychiatry 1984;41:934–41.
76 E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
[67] Ringstrom SJ, Suter DE, Hostetler JP, et al. Cortisol regulates secretion and pituitary
content of the two gonadotropins differentially in female rats: Effects of gonadotropin-
releasing hormone antagonist. Endocrinology 1992;130:3122–8.
[68] Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric
disorders in three sites. Arch Gen Psychiatry 1984;41:949–58.
[69] Rubin RT, Poland RE, Lesser IM, et al. Neuroendocrine aspects of primary endogenous
depression I. Cortisol secretory dynamics in patients and matched controls. Arch Gen
Psychiatry 1987;44:328–36.
[70] Rubin RT, Poland RE, Lesser IM. Neuroendocrine aspects of primary endogenous
depression VIII. Pituitary-gonadal axis activity in male patients and matched control
subjects. Psychoneuroendocrinology 1989;14:217–29.
[71] Rubinow DR, Schmidt PJ. Models for the development and expression of symptoms in
premenstrual syndrome. Psychiatr Clin North Am 1989;12:653–81.
[72] Rupprecht R, Rupprecht C, Rupprecht M, et al. Different reactivity of the hypothalamo-
pituitary-gonadal axis in depression and normal controls. Pharmacopsychiatry 1988;21:
438–9.
[73] Russel GFM, Beardwood CJ. Amenorrhea in feeding disorders: anorexia nervosa and
obesity. Psychother Psychosom 1970;18:359–64.
[74] Sachar EJ, Hellman L, Roffwarg HP, et al. Disrupted 24–hour patterns of cortisol secretion
in psychotic depressives. Arch Gen Psychiatry 1973;28:19–24.
[75] Sakakura M, Takebe K, Nakagawa S. Inhibition of leutenizing hormone secretion induced
by synthetic LRH by long term treatment with glucocorticoids in human subjects. J Clin
Endocrinol Metab 1975;40:774–9.
[76] Saketos M, Sharma N, Santoro NF. Suppression of the hypothalamic-pituiatry-ovarian
axis in normal women by glucocorticoids. Biol Reprod 1993;49:1270–6.
[77] Samuels MH, Luther M, Henry P, Ridgeway EC. Effects of hyocortisone on pulsatile
pituitary glycoprotein secretion. J Clin Endocrinol Metab 1994;78:211–315.
[78] Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-
related depression: A preliminary report. Am J Obstet Gynecol 2000;183:414–20.
[79] Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms
in women with premenstrual syndrome. N Engl J Med 1991;324:1174–9.
[80] Schwartz N, Justo S. Acute changes in serum gonadotropins and steroids following
orchidectomy in the rat: Role of the adrenal gland. Endocrinology 1977;100:1550–6.
[81] Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin and cortisol
secretion in male patients with major depression. Psychosom Med 1999;61:292–6.
[82] Suh BY, Liu JH, Berga SL, et al. Hypercortisolism in patients with functional
hypothalamic-amenorrhea. J Clin Endocrinol Metab 1988;66:733–739.
[83] Sutter DE, Schwartz NB. Effect of glucocorticoids on secretion of luteinizing hormone and
follicle-stimulating hormone by female rat pituitary cells in vitro. Endocrinology 1985;
117:849–54.
[84] Unden F, Ljunggren JG, Beck-Friis J, et al. Hypothalamic-pituitary-gonadal axis in major
depressive disorders. Acta Psychiatr Scand 1988;78:138–46.
[85] ValeW, Spiess J, Rivier J, et al. Characterization of a 41-residue ovine hypothalamic peptide
that stimulates secretions of corticotropin and beta-endorphin. Science 1981;213:1394–7.
[86] Villanueva AL, Schlosser C, Hopper B, et al. Increased cortisol production in women
runners. J Clin Endocrinol Metab 1986;63:133–6.
[87] Weissman M, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen
Psychiatry 1977;34:98–111.
[88] Winokur A, Amsterdam J, Caroff S, et al. Variability of hormonal responses to a series of
neuroendocrine challenges in depressed patients. Am J Psychiatry 1982;139:39–44.
[89] Winokur G, Clayton P. Family Studies: I. Two types of affective disorders separated
according to genetic and clinical factors. In: Wortis IJ, editor. Recent Advances in
Biological Psychiatry. New York: Plenum Press; 1967.
77E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
[90] Xiao E, Ferin M. The inhibitory action of corticotropin-releasing hormone in the
ovariectomized rhesus monkey is not mediated by ACTH. Biol Reprod 1988;38:763–76.
[91] Xiao E, Luckhaus J, Niemann W, et al. Acute inhibition of gonadotropin secretion by
corticotropin-releasing hormone in the primate: are the adrenal glands involved? Endo-
crinology 1989;124:1632–7.
[92] Yonkers KA, Bradshaw KD. Hormone replacement and oral contraceptive therapy:
Do they induce or treat mood symptoms. In: Gender Differences in Mood and Anxiety
Disorders, From Bench to Bedside. Leibenluft E (ed). Washington, DC: American
Psychiatric Press; 1999. p. 91–136.
[93] Young EA. Haskett RF, Watson SJ, et al. Loss of glucocorticoid fast feedback in
depression. Arch Gen Psychiatry 1991;48:693–9.
[94] Young EA, Midgley AR, Carlson NE, et al. Alteration in the Hypothalamic-Pituitary-
Ovarian axis in depressed women. Arch Gen Psychiatry 2000;57:1157–62.
[95] Young EA, Watson SJ, Kotun J, et al. Response to low dose oCRH in endogenous
depression: Role of cortisol feedback. Arch Gen Psychiatry 1990;47:449–57.
78 E.A. Young, A. Korszun / Endocrinol Metab Clin N Am 31 (2002) 63–78
